Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Performances of Spectral Domain Optical Coherence Tomography (OCT) for Distinguishing Glaucomatous Eyes (cirrusOCT)

This study has been completed.
Sponsor:
Information provided by:
Prince of Songkla University
ClinicalTrials.gov Identifier:
NCT01067482
First received: February 10, 2010
Last updated: March 22, 2010
Last verified: October 2009
  Purpose

The purpose of this study is to evaluate performances of each parameters of spectral domain (Cirrus) optical coherence tomography for distinguishing between normal eyes, glaucoma suspect and glaucomatous eyes


Condition
Glaucoma Patient
Glaucoma Suspect Patient
Normal Population
RNFL Thickness by Location
Macular Thickness by Location

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: The Performances of Spectral Domain Optical Coherence Tomography for Distinguishing Between Normal Eyes, Glaucoma Suspect and Glaucomatous Eyes

Resource links provided by NLM:


Further study details as provided by Prince of Songkla University:

Estimated Enrollment: 80
Study Start Date: September 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Glaucoma patients
Glaucoma suspect group
Normal population

Detailed Description:

Aim to determine which parameter of cirrus OCT is best sensitivity and specificity for glaucoma detection

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

glaucoma patient from glaucoma clinic that is POAG Glaucoma suspect cases normal population case

Criteria

Inclusion Criteria:

  • BCVA at least 20/60
  • refractive error +/- 5 D Or astig +/- 3 D
  • enrolled in 3 population group (glaucoma, glaucoma suspect or normal)

Exclusion Criteria:

  • VA less than 20/60
  • marked RF error
  • previous ocular trauma or surgery
  • unreliable visual field
  • poor signal cirrus OCT (less than 7)
  • other causes of optic nerve or macular disease other than glaucoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01067482

Locations
Thailand
Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University
Hat-yai,, Songkhla, Thailand., Thailand, 90110
Sponsors and Collaborators
Prince of Songkla University
Investigators
Principal Investigator: Weerawat Kiddee, MD Prince of Songkla University
  More Information

No publications provided

Responsible Party: Weerawat Kiddee, Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University Hat-yai,, Songkhla, Thailand., Thailand
ClinicalTrials.gov Identifier: NCT01067482     History of Changes
Other Study ID Numbers: EC 52-336-02-1-2
Study First Received: February 10, 2010
Last Updated: March 22, 2010
Health Authority: Thailand: Ethical Committee

Keywords provided by Prince of Songkla University:
OCT
spectral domain cirrus
glaucoma
glaucoma suspect
normal population

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases

ClinicalTrials.gov processed this record on November 20, 2014